Free webinar on Approach to Weed Out HIV and HCV in Special OUD Populations
19th Sep 2019 - Earn 1.5 CME Credit points
At the end of this CE activity, participants should be able to:
- Implement strategies for HIV and HCV testing in special OUD populations in correctional, VA, and rural settings.
- Apply evidence-based treatment approaches in patients with OUD with HIV or HCV infection or HIV/HCV co-infection.
- Identify patients with OUD at high risk for HIV infection who are candidates for HIV prevention strategies, including PrEP.
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Gilead Sciences, Inc.
Since 2002, CME Outfitters has delivered innovative evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. CME Outfitters focuses on delivering education to primary care, specialty audiences and community-based clinicians with strong expertise in neuroscience, gastroenterology, dermatology, rheumatology, immunology, virology, transplant, and cardiology. CME Outfitters is certified as a women’s business enterprise through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third-party certifier of businesses owned and operated by women in the United States Click here to learn more
David A. Wohl, MD
Professor of Medicine;
Site Leader, Global HIV Prevention & Treatment Research Site;
Co-Director, North Carolina AIDS Training & Education Center;
Co-Director, Viral Hemorrhagic Fever Clinical Research Group; Institute for Global Health & Infectious Diseases; The University of North Carolina (UNC) at Chapel Hill School of Medicine; Chapel Hill, NC
Carlos Malvestutto, MD, MPH
Division of Infectious Diseases
Ohio State University Wexner Medical Center
Jaimie P. Meyer, MD, MS, FACP
Assistant Professor of Medicine
Department of Internal Medicine,
Section of Infectious Disease, AIDS Program
Yale University School of Medicine
Clinical Assistant Professor
Division of Primary Care/Health Systems in Nursing
Yale School of Nursing; New Haven, CT
- OUD specialists
- Primary care physicians
- Mental health specialists
Injection drug use (IDU) has been fueled by the opioid crisis, resulting in a dramatic increase in hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. People with opioid use disorder (OUD) are 28 times more likely to contract HIV, and one in 10 new HIV infections is attributed to IDU. Further, the CDC reported a 233% increase in new HCV infections between 2010-2016.
Although effective treatments for HIV and HCV exist and are readily available, barriers related to OUD make treatment difficult in this population, especially in the rural, correctional, and VA settings.
In this CME Outfitters Live and On Demand, expert faculty discuss strategies for HIV and HCV testing in special OUD populations, applying evidence-based treatment approaches, as well as prevention strategies, including PrEP, for patients with OUD at high risk for HIV infection.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr.David A. Wohl
Dr.Wohl reports that he receives research support from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is a consultant for Gilead Sciences, Inc.
Dr.Malvestutto reports that he serves on the advisory board for ViiV Healthcare.
Dr.Jaimie P. Meyer
Dr.Meyer reports that she receives research support from Gilead Sciences, Inc.